Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Onnit To Announce Alpha BRAIN™ Pilot Study Results
  • USA - English


News provided by

Onnit

Feb 14, 2014, 15:00 ET

Share this article

Share toX

Share this article

Share toX

Alpha BRAIN™ By Onnit
Alpha BRAIN™ By Onnit

Austin, Texas (PRWEB) February 14, 2014 -- Results from a pilot study entitled “A Proof of Concept Study for a Randomized Double-Blind, Placebo Controlled, Parallel Group, Efficacy Study of Alpha BRAIN™ Administered Orally,” conducted by the Boston Center for Memory will be presented at the annual International Neuropsychological Society (INS) meeting in Seattle, February 12th-15th.

To download a PDF of the poster, click here or visit https://www.onnit.com/clinical-studies/alpha-brain-clinical-trial/.

This pilot study is a very important milestone. To achieve statistical significance in key cognitive markers with a study population of this size is very encouraging, and we eagerly look forward to the results of the larger study currently underway.

Post this

The purpose of the study was to test the efficacy of the Alpha BRAIN™ as well as devise a logical design for the future of testing products aimed at cognitive enhancement. Specific cognitive areas that were evaluated during the study included memory, attention and executive functioning as well as Alpha BRAIN™ effect on sleep.

The study followed a randomized, double-blind design and included a placebo run-in for all subjects in order to minimize any potential placebo effect. During the study, seventeen cognitively healthy subjects were randomized to receive a six-week supplementation of either Alpha BRAIN™ or a placebo. Prior to starting study treatment, each subject underwent a battery of neuropsychological tests to assess cognitive functioning. After six-weeks of following the manufacturer's recommended dose of either Alpha BRAIN™ or placebo, the neuropsychological testing battery was repeated.

Lead researcher Todd M. Solomon, PhD, who will be presenting the data at the INS conference, commented, “We feel this is a great example of how the same rigorous methodology and design used in experimental medication trials can be applied to research involving supplements. While the number of subjects in this pilot study is too small to allow for extrapolation of the results, we are excited to apply this design to a larger study."

Results from the pilot study demonstrated that overall compliance with study treatment was excellent. Further, both study treatment and placebo were well tolerated. With regard to cognitive outcome measures, results indicated that following the six-week study period, the control group neither significantly improved nor deteriorated on neuropsychological measures. Of the sixteen neuropsychological tests included in the analysis, the group receiving Alpha BRAIN™ showed statistically significant improvement on two of the outcome measures in areas that relate to verbal memory and executive function. While the small sample size limits the generalizability of this study, the findings are highly encouraging and a larger study, currently underway, will include more subjects and utilize unique biomarkers to provide greater insight to the effects of Alpha BRAIN™ on healthy individuals.

Aubrey Marcus, CEO of Onnit commented further. “We are learning that the clinical trial process requires a great deal of patience, but Onnit remains committed to marrying the best earth grown ingredients formulas, to the most rigorous scientific analysis. This pilot study is a very important milestone. To achieve statistical significance in key cognitive markers with a study population of this size is very encouraging, and we eagerly look forward to the results of the larger study currently underway.”

Onnit also expects to present separate data from a full clinical trial on the T+ formulation later in the spring. Results for the larger Alpha BRAIN™ trial are expected in 2015.

For scientific or medical inquiry contact Jarrett Leech, Jarrett(at)Onnit(dot)com.
For general press, or sales inquiry contact Orlando Rios, Orlando(at)Onnit(dot)com.

ABOUT ONNIT:
Onnit is an Austin, TX based health and wellness company focused on encouraging peak performance through a combination of unique products and actionable information. With strategy from leading professional athletes and medical practitioners, Onnit has focused on creating naturally derived nutritional supplements and functional foods based upon the latest ingredient science and dietary research. Their flagship nootropic, AlphaBRAIN™, is designed to help the body foster optimal brain function with a combination of neuro-specific antioxidants and neurotransmitter precursors. Other formulas for mood, athletic endurance, immune health, and testosterone round out their list of acclaimed formulations. Valuing the importance of the body as well as the mind, Onnit offers functional fitness equipment designed to enhance real world strength and endurance--The final piece on the roadmap to Total Human Optimization.

Orlando Rios, Onnit, http://www.onnit.com, +1 512-691-9097, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.